Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Clonal chromosomal abnormalities in CD34+/CD38− hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors

Clonal chromosomal abnormalities in CD34+/CD38− hematopoietic cells from cytogenetically normal... Letters to the Editor N von Bubnoff, C Rummelt, H Menzel, M Sigl, or not amenable to conventional therapy for the disease. Blood C Peschel and J Duyster 2005; 105: 986–993. 3. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, 5 Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X Technische Universita¨tMu¨nchen, Mu¨nchen, Germany et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008; 100: 184–198. E-mail: [email protected] 6 Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic References stem cell transplantation. Blood 2009; 113: 6567–6571. 7 Heidel F, Solem FK, Breitenbuecher F, Lipka DB, Kasper S, Thiede 1 Swerdlow SH, Campo E, Harris NL, Pileri SA, Stein H, Thiele J MH et al. Clinical resistance to the kinase inhibitor PKC412 in et al. WHO Classification of Tumours of Haematopoietic and acute myeloid leukemia by mutation of Asn-676 in the FLT3 Lymphoid Tissues, 4th edn. IARC Press: Lyon, 2008. tyrosine kinase domain. Blood 2006; 107: 293–300. 2 Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Leukemia Springer Journals

Clonal chromosomal abnormalities in CD34+/CD38− hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/clonal-chromosomal-abnormalities-in-cd34-cd38-hematopoietic-cells-from-dapGLVUj7W

References (9)

Publisher
Springer Journals
Copyright
Copyright © 2010 by Macmillan Publishers Limited
Subject
Medicine & Public Health; Medicine/Public Health, general; Internal Medicine; Intensive / Critical Care Medicine; Cancer Research; Oncology; Hematology
ISSN
0887-6924
eISSN
1476-5551
DOI
10.1038/leu.2010.123
Publisher site
See Article on Publisher Site

Abstract

Letters to the Editor N von Bubnoff, C Rummelt, H Menzel, M Sigl, or not amenable to conventional therapy for the disease. Blood C Peschel and J Duyster 2005; 105: 986–993. 3. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, 5 Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X Technische Universita¨tMu¨nchen, Mu¨nchen, Germany et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008; 100: 184–198. E-mail: [email protected] 6 Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic References stem cell transplantation. Blood 2009; 113: 6567–6571. 7 Heidel F, Solem FK, Breitenbuecher F, Lipka DB, Kasper S, Thiede 1 Swerdlow SH, Campo E, Harris NL, Pileri SA, Stein H, Thiele J MH et al. Clinical resistance to the kinase inhibitor PKC412 in et al. WHO Classification of Tumours of Haematopoietic and acute myeloid leukemia by mutation of Asn-676 in the FLT3 Lymphoid Tissues, 4th edn. IARC Press: Lyon, 2008. tyrosine kinase domain. Blood 2006; 107: 293–300. 2 Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer

Journal

Leukemia – Springer Journals

Published: Jun 10, 2010

There are no references for this article.